A novel potential therapy for diabetic nephropathy and vascular complications: Protein kinase C β inhibition

American Journal of Kidney Diseases

Volumn 42, Issue 3, 2003, Pages 456-465

  Tuttle, Katherine R ^a   Anderson, Pamela W ^b  

^a Heart Institute of Spokane   (United States)

^b NONE

Author keywords

Endothelial function; Hyperglycemia; Kidney; Ruboxistaurin; Signal transduction

Indexed keywords

ALBUMIN; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BISINDOLYLMALEIMIDE; CAPTOPRIL; COLLAGEN TYPE 4; DIACYLGLYCEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRONECTIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IRBESARTAN; ISOENZYME; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PLACEBO; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C DELTA; PROTEIN KINASE C EPSILON; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; UNINDEXED DRUG;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMORBIDITY; DIABETES CONTROL; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG UTILIZATION; DYSLIPIDEMIA; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; EXTRACELLULAR MATRIX; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION; MESANGIUM; META ANALYSIS; MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PROTEIN RESTRICTION; PROTEIN SYNTHESIS; RAT STRAIN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; SURVIVAL RATE; TISSUE LEVEL; URINARY EXCRETION;

EID: 0041358574     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(03)00741-8     Document Type: Article

References (79)

1. US Renal Data System: Annual Data Report: Incidence and Prevalence, 2001. Am J Kidney Dis 38:S37-S52, 2001 (suppl 3)
2. Nelson RG, Knowler WC, Pettitt DJ, Bennett PH: Kidney diseases in diabetes, in Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH (eds): Diabetes in America. Bethesda, MD, The National Institutes of Health, 1995, pp 349-400
3. Parving HH, Smidt UM, Hommel E, et al: Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis 22:188-195, 1993
4. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development of progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:997-986, 1993
5. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
6. Shichiri M, Kishikawa H, Ohkubo Y, Wake N: Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23:B21-B29, 2000
7. Phillips CA, Molitch ME: The relationship between glucose control and the development and progression of diabetic nephropathy. Curr Diabetes Rep 2:523-529, 2002
8. Alaveras AEG, Thomas SM, Sagriotis A, Viberti GC: Promoters of progression of diabetic nephropathy: The relative roles of blood glucose and blood pressure control. Nephrol Dial Transplant 12:71-74, 1997
9. Mulec H, Blohme G, Grande B, Bjork S: The effect of metabolic control on rate of decline in renal function in insulin-dependent diabetes mellitus with overt nephropathy. Nephrol Dial Transplant 13:651-655, 1998
10. Tarnow L, Rossing P, Gall MA, Nielsen FS, Parving HH: Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 17:1247-1251, 1994
11. Bakris GL, Williams M, Dworkin L, et al: Special report: Diabetes mellitus and hypertension. Preserving renal function in adults with hypertension and diabetes: A consensus approach. Am J Kidney Dis 36:646-661, 2000
12. Lewis EJ, Hunsicker LG, Bain RP, Rohde R, for the Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
13. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259, 2000
14. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
15. Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
16. Parving H-H, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, for the Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropatby in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
17. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77:1925-1930, 1986
18. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 93:2431-2437, 1994
19. Ray PE, Bruggeman LA, Horikoshi S, Aguilera G, Klotman PE: Angiotensin II stimulates human fetal mesangial cell proliferation and fibronectin biosynthesis by binding to AT1 receptors. Kidney Int 45:177-184, 1994
20. Wolf G, Haberstroh U, Neilson EG: Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 140:95-107, 1992
21. Zatz R, Meyer TW, Rennke HG, Brenner BM: Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci U S A 82:5963-5967, 1985
22. Brenner BM, Meyer TW, Hostetter TH: Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652-659, 1982
23. Tuttle KR, Puhlman ME, Cooney SK, Short RA: Effect of amino acids and glucagon on renal hemodynamics in type 1 diabetes. Am J Physiol 282:FI03-F112, 2002
24. Tuttle KR, Bruton JL: Effect of insulin therapy on renal hemodynamic response to amino acids and renal hypertrophy in non-insulin-dependent diabetes. Kidney Int 42:167-173, 1992
25. Tuttle KR, Bruton JL, Perusek MC, Lancaster JL, Kopp DT, DeFronzo RA: Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. N Engl J Med 324:1626-1632, 1991
26. Levey AS, Greene T, Beck GJ, et al: Dietary protein restriction and the progression of chronic renal disease: What have all of the results of the MDRD study shown? J Am Soc Nephrol 10:2426-2439, 1999
27. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH: The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: A meta-analysis. Ann Intern Med 124:627-632, 1996
28. Hanson HP, Tauber-Lassen E, Jensen BR, Parving H-H: Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int 62:220-228, 2002
29. Ruilope LM, Casal MC, Praga M, et al: Additive antiproteinuric effect of converting enzyme inhibition and a low protein intake. J Am Soc Nephrol 3:1307-1311, 1992
30. Gansevoort RT, de Zeeuw D, de Jong PE: Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease. Nephrol Dial Transplant 10:497-504, 1995
31. Walser M: Nutritional therapy for progressive renal failure. Curr Opin Nephrol Hypertens 3:301-304, 1994
32. Ritz E, Stefanski A: Diabetic nephropathy in type 2 diabetes. Am J Kidney Dis 27:167-194, 1996
33. Maroni BJ, Mitch WE: Role of nutrition in the prevention of the progression of renal disease. Annu Rev Nutr 17:435-455, 1997
34. Nishimura M, Sasaki T, Ohishi A, et al: Angiotensin-converting enzyme inhibitors and probucol suppress the time-dependent increase in urinary type IV collagen excretion of type II diabetes mellitus patients with early diabetic nephropathy. Clin Nephrol 58:96-103, 2001
35. Orchard TJ, Medsci M, Forest KY-Z, Kuller LH, Becker DJ: Lipid and blood pressure treatment goals for type 1 diabetes. Diabetes Care 24:1053-1059, 2001
36. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R: Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 158:998-1004, 1998
37. Mulec H, Johnsen SA, Wiklund O, Björck S: Cholesterol: A renal risk factor in diabetic nephropathy. Am J Kidney Dis 22:196-201, 1993
38. Nakao T, Yoshino M, Matsumoto H, et al: Low-density lipoprotein apheresis retards progression of hyperlipidemic overt diabetic nephropathy. Kidney Int Suppl 71:S206-S209, 1999
39. Tonolo G, Ciccarese M, Brizzi P, et al: Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 20:1891-1895, 1997
40. Smulders YM, Van Eeden AE, Stehouwer CDA, Weijers NM, Slaats EH, Silberbusch J: Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? Euro J Clin Invest 27:997-1002, 1997
41. Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 59:260-269, 2001
42. Craven PA, DeRubertis FR: Protein kinase C is activated in glomeruli from streptozotocin diabetic rats: Possible mediation by glucose. J Clin Invest 83:1667-1675, 1989
43. Ayo SH, Radnik R, Garoni JA, Troyer DA, Kreisberg JI: High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures. Am J Physiol 261:F571-F577, 1991
44. Protein Kinase C. Online Mendelian Inheritance in Man: Baltimore, MD, McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University; and Bethesda, MD, National Center for Biotechnology Information, National Library of Medicine. Available at: http://www.ncbi.nlm.nih.gov/omim/. Accessed: March 6, 2003
45. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL: Preferential elevation of protein kinase C isoform βII and diacylglycerol levels in the aorta and heart of diabetic rats: Differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci U S A 89:11059-11063, 1992
46. Shiba T, Inoguchi T, Sportsman JR, Heath WF, Bursell S, King GL: Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol 265:E783-E793, 1993
47. Craven PA, Davidson CM, DeRubertis FR: Increase in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids. Diabetes 39:667-674, 1990
48. Williams B, Schrier RW: Characterization of glucose-induced in situ protein kinase C activity in cultured vascular smooth muscle cells. Diabetes 41:1464-1472, 1992
49. Williams B, Schrier RW: Glucose-induced protein kinase C activity regulates arachidonic acid release and eicosanoid production by cultured glomerular mesangial cells. J Clin Invest 92:2889-2896, 1993
50. DeRubertis FR, Craven PA: Activation of protein kinase C in glomerular cells in diabetes. Mechanisms and potential links to the pathogenesis of diabetic glomerulopathy. Diabetes 43:1-8, 1994
51. Kikkawa R, Haneda M, Uzu T, Koya D, Sugimoto T, Shigeta Y: Translocation of protein kinase C α and ζ in rat glomerular mesangial cells cultured under high glucose conditions. Diabetologia 37:838-841, 1994
52. Ishii H, Jirousek MR, Koya D, et al: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 272:728-731, 1996
53. Jirousek MR, Gillig JR, Gonzalez CM, et al: (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9: 16,21dimetheno-1H,13H-dibenzo[e,k]pyrrolo[3,4-h] [1,4,13]-oxadiazacyclohexadecene-1,3(2H)-dione (ruboxistaurin) and related analogues: Isozyme selective inhibitors of protein kinase Cβ. J Med Chem 39:2664-2671, 1996
54. Koya D, Jirousek MR, Lin Y-W, Ishii H, Kuboki K, King GL: Characterization of protein kinase C β isoform activation on the gene expression of transforming growth factor-β, extracellular matrix components and prostanoids in the glomeruli of diabetic rats. J Clin Invest 100:115-126, 1997
55. Lee SM, Bressler R: Prevention of diabetic nephropathy by diet control in the db/db mouse. Diabetes 30:106-111, 1981
56. Koya D, Haneda M, Nakagawa H, et al: Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 14:439-447, 2000
57. Kelly DJ, Wilkinson-Berka JL, Allen TJ, Cooper ME, Skinner SL: A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int 54:343-52, 1998
58. Kelly DJ, Zhang Y, Hepper C, et al: PKC β inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 52:512-518, 2003
59. Whiteside CI, Dlugosz JA: Mesangial cell protein kinase C isozyme activation in the diabetic milieu. Am J Physiol 282:F975-F980, 2002
60. Boesch DM, Garvin GL: Age-dependent activation of PKC isoforms by AII in the proximal nephron. Am J Physiol 281:R861-867, 2001
61. Osicka TM, Yu Y, Lee V, Ranagiotopoulos S, Kemp BE, Jerums G: Aminoguanidine and ramipril prevent diabetes induced increases in protein kinase C activity in glomeruli, retina and mesenteric artery. Clin Sci 100:249-257, 2001
62. Nagahama T, Hayashi K, Ozawa Y, Takenaka T, Saruta T: Role of protein kinase C in angiotensin-induced constriction of renal microvessels. Kidney Int 57:215-223, 2000
63. Scivittaro V, Ganz MB, Jaken S: AGEs induce oxidative stress and activate protein kinase C-βII in neonatal mesangial cells. Am J Physiol 278:F676-F683, 2000
64. Nishikawa T, Edelstein D, Du XL, et al: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787-790, 2000
65. Tuttle KR, Puhlman ME, Cooney SK, Short R: Urinary albumin and insulin as predictors of coronary artery disease: An angiographic study. Am J Kidney Dis 34:918-925, 1999
66. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 27:2033-2039, 1996
67. Valmadrid CT, Klein R, Moss SE, Klein BEK: The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 160:1093-1100, 2000
68. Kannel WB, McGee DL: Diabetes and cardiovascular disease. JAMA 241:2035-2038, 1979
69. Clarkson P, Celermajer DS, Donald AE, et al: Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low-density lipoprotein cholesterol levels. J Am Coll Cardiol 28:573-579, 1996
70. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilatation in patients with insulin-dependent diabetes mellitus. Circulation 88:2510-2516, 1993
71. Craven PA, Studer RK, Felder J, Phillips S, DeRubertis FR: Nitric oxide inhibition of transforming growth factor-beta and collagen synthesis in mesangial cells. Diabetes 46:671-681, 1997
72. Trachtman H, Futterweit S, Crimmins DL: High glucose inhibits nitric oxide production in cultured rat mesangial cells. J Am Soc Nephrol 8:1276-1282, 1997
73. Chen S, Cohen MP, Lautenslager GT, Shearman CW, Ziyadeh FN: Glycated albumin stimulates TGF-β1 production and protein kinase C activity in glomerular endothelial cells. Kidney Int 59:673-681, 2001
74. Kuboki K, Jiang ZY, Takahara N, et al: Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: A specific vascular action of insulin. Circulation 101:676-681, 2000
75. Calver A, Collier J, Vallance P: Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 90:2548-2554, 1992
76. Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Creager MA: Inhibition of protein kinase Cβ prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res 90:107-111, 2002
77. Aiello LP, Bursell SE, Devries T, Alatorre C, King, GL, Ways DK: Amelioration of abnormal retinal hemodynamics by a protein kinase C β selective inhibitor (LY333531) in patients with diabetes: Results of a phase 1 safety and pharmacodynamic clinical trial. Invest Ophthal Vis Sci 40: S192, 1999 (suppl, abstr)
78. Ritz E, Rychlik I, Locatelli F, Halimi S: End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 35:795-808, 1999
79. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW: The myeloperoxidase system of human phagocytes generates N-epsilon-(carboxymethyl)lysine on proteins: A mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 104:103-113, 1999